1597. Randomized-Controlled Trial Evaluating The Outcome Between Switching to Tenofovir Disoproxil Fumarate(TDF)/Lamivudine(3TC)/Dolutegravir(DTG) Versus Maintaining The Current NNRTI Or Boosted-PI-containing Regimen in PLWH in Thailand – A Pilot Study from Single Center

BACKGROUND: The Thai and WHO HIV 2022 guidelines have recently adopted TDF/3TC/DTG (TLD; single tablet) as the preferred regimen replacing NNRTI- or boosted-PI-based cART among both treatment-naïve and -experienced PLWH. Virologic and metabolic outcomes are scarce after switching to TLD compared wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Patamatamkul, Samadhi, Chancharusiri, Kongkarn, Putcharoen, Opass
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678113/
http://dx.doi.org/10.1093/ofid/ofad500.1432

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678113/
http://dx.doi.org/10.1093/ofid/ofad500.1432

Ejemplares similares